SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

6 candidates mapped to SDH-deficient disease pathways

All (27)established (4)clinical trial (4)preclinical (13)theoretical (6)
Niraparib

Zejula

theoretical

PARP inhibitor (PARP1/2)

Sdh Driven Hrd
Evidence Score
45
FDA Approved
Erdafitinib

Balversa

theoretical

Pan-FGFR inhibitor (FGFR1/2/3/4), FDA-approved

Fgfr Signaling
Evidence Score
42
FDA Approved
Birabresib

OTX015, MK-8628

theoretical

BET bromodomain inhibitor (pan-BRD2/3/4)

Epigenetic Dysregulation
Evidence Score
33
Panobinostat

Farydak

theoretical

Pan-HDAC inhibitor

Epigenetic Dysregulation
Evidence Score
30
FDA Approved
Enasidenib

Idhifa

theoretical

IDH2 inhibitor

Epigenetic Dysregulation
Evidence Score
28
FDA Approved
Epacadostat

INCB024360

theoretical

IDO1 inhibitor (indoleamine 2,3-dioxygenase 1 inhibitor)

Succinate Immune Evasion
Evidence Score
22